|By PR Newswire||
|July 31, 2014 06:26 PM EDT||
NEW YORK, July 31, 2014 /PRNewswire/ - Canaccord Genuity is pleased to announce that Marko Kozul, M.D. has agreed to join its Equity Research team as a Managing Director covering biotechnology companies.
"The addition of Dr. Marko Kozul complements our existing global coverage of the Healthcare sector and affirms our commitment to providing clients with high quality, independent equity research coverage in dynamic growth sectors," stated Dan Daviau, President of Canaccord Genuity Inc. (US). "In addition to an established track record in equity research, Marko brings deep clinical and advisory experience to his role, which gives him an advanced understanding of the industry drivers impacting his coverage universe."
Based in the firm's San Francisco office, Dr. Kozul will focus on companies with advanced biotechnology platforms in the areas of neurology, immunology, obesity, oncology, and orphan infectious diseases. He joins senior Healthcare analysts John Newman and Corey Davis, building upon the firm's existing US life science practice.
Dr. Kozul joins Canaccord Genuity from Leerink Partners where he served as a senior biotechnology analyst and was previously analyst at ThinkEquity Partners and Jefferies & Company. Earlier in his career, he worked as the Research Director for Variant Medical Consulting Group and as a consultant for the Medical & Referral Source Inc. Dr. Kozul earned a Bachelor of Science in Cellular & Molecular Biology from the University of Michigan and an M.D. from the School of Medicine at International University of the Health Sciences. He is a member in good standing of the American Medical Association, the American Society of Clinical Oncology and the American Association for Cancer Research, the American Society of Hematology and the American Academy of Ophthalmology.
Canaccord Genuity's global equity research team now includes nine senior healthcare analysts across three continents, covering Biotechnology, Specialty Pharmaceuticals, Medical Devices, Medical Diagnostics, Life Sciences Tools and Healthcare Services. At present, Canaccord Genuity has nearly 150 equity research professionals globally and more than 950 companies under coverage.
ABOUT CANACCORD GENUITY:
Canaccord Genuity is the global capital markets division of Canaccord Genuity Group Inc. (TSX: CF, LSE: CF.), offering institutional and corporate clients idea-driven investment banking, merger and acquisition, research, sales and trading services from offices in 10 countries worldwide. Our team of nearly 1,000 capital markets and advisory professionals has industry and transactional expertise in 18 key sectors of the global economy. We are committed to providing valued services to our clients throughout the entire lifecycle of their business and operating as a gold standard independent investment bank - expansive in resources and reach, but targeted in industry expertise, market focus and individual client attention.
More information is available at www.canaccordgenuity.com.
ABOUT CANACCORD GENUITY GROUP INC.:
Through its principal subsidiaries, Canaccord Genuity Group Inc. (the "Company") is a leading independent, full-service financial services firm, with operations in two principal segments of the securities industry: wealth management and capital markets. Since its establishment in 1950, the Company has been driven by an unwavering commitment to building lasting client relationships. We achieve this by generating value for our individual, institutional and corporate clients through comprehensive investment solutions, brokerage services and investment banking services. The Company has offices in 10 countries worldwide, including Wealth Management offices located in Canada, Australia, the UK and Europe. Canaccord Genuity, the international capital markets division, operates in Canada, the US, the UK, France, Germany, Ireland, Hong Kong, China, Singapore, Australia and Barbados. To us there are no foreign markets.™
Canaccord Genuity Group Inc. is publicly traded under the symbol CF on the TSX and the symbol CF. on the London Stock Exchange.
SOURCE Canaccord Genuity Inc.
Mar. 23, 2017 06:00 PM EDT Reads: 1,201
Mar. 23, 2017 04:15 PM EDT Reads: 2,383
Mar. 23, 2017 03:45 PM EDT Reads: 1,693
Mar. 23, 2017 03:45 PM EDT Reads: 537
Mar. 23, 2017 03:30 PM EDT Reads: 1,531
Mar. 23, 2017 03:30 PM EDT Reads: 1,646
Mar. 23, 2017 03:00 PM EDT Reads: 6,151
Mar. 23, 2017 02:30 PM EDT Reads: 4,022
Mar. 23, 2017 02:30 PM EDT Reads: 1,388
Mar. 23, 2017 02:30 PM EDT Reads: 2,317
Mar. 23, 2017 02:15 PM EDT Reads: 1,123
Mar. 23, 2017 01:00 PM EDT Reads: 2,065
Mar. 23, 2017 12:45 PM EDT Reads: 1,626
Mar. 23, 2017 12:30 PM EDT Reads: 1,101
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Mar. 23, 2017 12:30 PM EDT Reads: 1,003